Testing a new drug plus chemo for stage 4 colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage 4 colorectal cancer that has spread to other parts of your body and is confirmed by a biopsy.
- You should not have had any previous treatment (like chemotherapy) for the cancer that has spread.
- Your health status should allow you to be up and active (ECOG score 0 or 1) — meaning you can do most daily activities without help.
- You must have at least one tumor that can be measured on a scan (like a CT scan).
- Your liver, kidney, and bone marrow function must be adequate (normal lab results).
- You cannot have certain genetic types of colorectal cancer (BRAF V600E mutation or MSI-high/dMMR), active brain metastases, serious bleeding or lung problems, recent major surgery, or uncontrolled autoimmune or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This study tests a new combination treatment for advanced colorectal cancer that has stopped responding to standard treatments or is newly diagnosed. It aims to see if the combination can shrink tumors or slow their growth.
Hear when a new Intestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.